Cramer‘s Analyst Says Eli Lilly’s GLP-1 Stock Rally Has Years Left to Run
Eli Lilly (LLY) posted a blowout quarter, and Mad Money says the GLP-1 drugmakers stock story is far from over. Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks. Sponsored Sponsored Why Eli Lillys GLP-1 Stock Still Has Room to Run The comment came during a viewer question about how price targets get set. Cramer raised Eli Lilly and Nvidias runs specifically when asking about the process. Marks, the CNBC Investing Clubs portfolio analyst, said stocks like these need a longer time horizon than most. “Stocks like that you also have to look out years out in advance, too. Especially in the case of Eli Lilly, where it‘s more of towards the end of the decade is where it’s GLP-1 sales.” — Jeff Marks, CNBC Investing Club portfolio analyst, on Mad Money Eli Lillys second-quarter results back that framing. Revenue hit $23 billion, up 48% year over year. A 60% jump in sales volume offset a 13% drop in realized prices. Management raised full-year revenue guidance to a range of $85 billion to $87 billion. Mounjaro sales rose 91% to $9.9 billion worldwide. Zepbounds U.S. revenue grew 44% to $4.9 billion. Sponsored Sponsored Cramers other 2026 stock picks lean on similarly durable, multi-year themes rather than short-term